Number of Participants Diagnosed With Sarcoidosis by Bronchoscopic Transbronchial Needle Aspiration After COVID- 2019 .

NCT06043882 | Completed

• 1 other identifier: FMASU-R 151/2022
• Study Type: observational
• Target: 55
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to learn about sarcoidosis development after COVID-19 infection. The main question it aims to answer is:

• prevalence of Sarcoidosis among patients previously infected with COVID-19. Participants will:
• provide previous positive RT-PCR for COVID-19
• Have computed tomography of the Chest with suggestive findings of sarcoidosis
• Have bronchoscopic guided biopsies and pathological analysis to detect number of patients with sarcoidosis.

Conditions

Sarcoidosis; COVID-19

Keywords

Sarcoidosis; COVID-19; SARS-CoV-2; Granulomatous disease

Outcome Measures

Primary Outcomes (1)

• Number and risk factors of sarcoidosis development after COVID -19 infection as diagnosed by TBNA guided tissue biopsies in bronchoscopy unit, chest department, Ain Shams university.

  Number of COVID-19 patients diagnosed by TBNA guided biopsies as having granulomatous tissue suggesting sarcoidosis development, and risk factors that associate its development.

  6 months

Study Arms (1)

the relation between COVID-19 infection and the development of sarcoidosis .

All patients were subjected to the following : history taking , clinical examination , radiological assessment by CT chest , fiberoptic bronchoscopy where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination and if the patient had past history of COVID-19 infection with previous positive RT-PCR.

Procedure: flexible bronchoscopy

Interventions

flexible bronchoscopy PROCEDURE

fiberoptic bronchoscopy was done where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination

the relation between COVID-19 infection and the development of sarcoidosis .

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients previously diagnosed as COVID -19 by RT-PCR ,with mediastinal or hilar lymphadenopathy with or without lung infiltrates referred to bronchoscopy unit ,Chest Department, Ain-Shams University Hospital for diagnosis.

You may qualify if:

• All adult patients with previous positive RT-PCR for COVID -19 and CT chest findings of mediastinal and or hilar lymphadenopathy with or without lung infiltrate will be included. .

You may not qualify if:

• Patients younger than 18 years old Patients
• Patients refuse to participate in the study
• Patients previously diagnosed as sarcoidosis

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Hoda atiatullah

Cairo, 02, Egypt

Location

MeSH Terms

Conditions

Sarcoidosis; COVID-19

Condition Hierarchy (Ancestors)

Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Hypersensitivity, Delayed; Hypersensitivity; Immune System Diseases; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Hoda A Mohamed, MD

  faculty of medicine, Ain Shams university

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 31, 2023
• First Posted: September 21, 2023
• Study Start: November 1, 2022
• Primary Completion: April 30, 2023
• Study Completion: May 30, 2023
• Last Updated: September 22, 2023

Record last verified: 2023-07

Locations

EG (1)